LANGHORNE, PA – Congressman Brian Fitzpatrick (PA-08) will spend his district work period meeting with constituents, local leaders, law enforcement and others to discuss work being done in Congress to address the nation’s opioid epidemic and ensure local concerns and solutions are part of the national discussion.
Fitzpatrick joins 46 freshman in signing ‘Commitment to Civility’ document
WASHINGTON, D.C. – Congressman Brian Fitzpatrick (PA-08) has joined 45 Democrat and Republican freshman members in signing a ‘Commitment to Civility’ pledge that seeks to restore collegiality, trust and civility to Congress, encourage productive dialogue, and work to build consensus and the public's trust in America’s institutions.
Annual 8th District Tour Will Focus on Finding Ways to Help Bucks, Montgomery Co. Small Businesses Thrive
WARMINSTER, PA – Congressman Brian Fitzpatrick (PA-08) has launched a district-wide small business listening tour aimed at learning more about Bucks and Montgomery county small businesses and ensuring their voice is represented in Congress.
Findings show serious shortfalls in device reporting surrounding power morcellators
WASHINGTON, D.C. – Congressman Brian Fitzpatrick (PA-08) and Congresswoman Louise Slaughter (NY-25) and a bipartisan group of members have announced the release of a long-awaited Government Accountability Office (GAO) report (attached) into the Food & Drug Administration’s (FDA) approval of power morcellators and the failure of the reporting system
Homeland Security Committee hearing focuses on America’s borders
WASHINGTON, D.C. – Congressman Brian Fitzpatrick (PA-08) questioned Department of Homeland Security Secretary John Kelly Tuesday on a number of issues, including the security of our nation’s borders and the connection between border control and combating Pennsylvania’s opioid epidemic.
Bill would increase access to potentially lifesaving treatment, care
WASHINGTON, D.C. – Congressmen Brian Fitzpatrick (PA-08) and Andy Biggs (AZ-05) introduced the Right to Try Act of 2017 Monday, legislation which would ensure that terminally ill patients, together with their physicians, and pharmaceutical manufacturers are allowed to administer investigational treatments where no alternative exists.